| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PNAS..109.2078V |
| P8978 | DBLP publication ID | journals/pnas/VolkmerSCHTKWPC12 |
| P356 | DOI | 10.1073/PNAS.1120605109 |
| P932 | PMC publication ID | 3277552 |
| P698 | PubMed publication ID | 22308455 |
| P5875 | ResearchGate publication ID | 221808957 |
| P50 | author | Irving Weissman | Q884581 |
| Yair Lotan | Q61862568 | ||
| A Alizadeh | Q73440211 | ||
| Matt van de Rijn | Q73902580 | ||
| Theresa A Storm | Q89520909 | ||
| Debashis Sahoo | Q89636466 | ||
| Chad Tang | Q90237469 | ||
| Robert Chin-Yao Ting | Q112066753 | ||
| Jens-Peter Volkmer | Q117277104 | ||
| Humberto Contreras-Trujillo | Q117277105 | ||
| Linda D Shortliffe | Q117277106 | ||
| P2093 | author name string | Stephen B Willingham | |
| Andrew H Beck | |||
| Seth P Lerner | |||
| Antonina V Kurtova | |||
| Philip Levy Ho | |||
| Keith S Chan | |||
| Guilherme Godoy | |||
| Benjamin I Chung | |||
| Senthil K Pazhanisamy | |||
| P2860 | cites work | Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells | Q24657020 |
| Cancer statistics, 2010 | Q27860525 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development | Q28513360 | ||
| Purification and unique properties of mammary epithelial stem cells | Q29616497 | ||
| A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment | Q30421675 | ||
| Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder | Q33217204 | ||
| Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells | Q33349898 | ||
| Identification of side population cells from bladder cancer cells by DyeCycle Violet staining | Q33369037 | ||
| Generation of a concise gene panel for outcome prediction in urinary bladder cancer | Q33561596 | ||
| Cancer stem cells in bladder cancer: a revisited and evolving concept | Q33639897 | ||
| Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer | Q33650639 | ||
| MiDReG: a method of mining developmentally regulated genes using Boolean implications | Q33778561 | ||
| Everything you wanted to know about the bladder epithelium but were afraid to ask. | Q33932620 | ||
| Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state | Q34178901 | ||
| Stem cell research: paths to cancer therapies and regenerative medicine | Q34452462 | ||
| Keratin expression in human tissues and neoplasms | Q34636832 | ||
| Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. | Q34698294 | ||
| Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression | Q34755858 | ||
| A four-gene signature predicts disease progression in muscle invasive bladder cancer. | Q35017006 | ||
| Urothelial tumorigenesis: a tale of divergent pathways | Q36234720 | ||
| Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer | Q36529700 | ||
| Boolean implication networks derived from large scale, whole genome microarray datasets | Q37384974 | ||
| Regional copy number-independent deregulation of transcription in cancer | Q40209266 | ||
| Epidermal differentiation and keratin gene expression | Q40387479 | ||
| Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers | Q42457867 | ||
| Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder | Q42523966 | ||
| Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease | Q45099291 | ||
| Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. | Q51703160 | ||
| Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. | Q51955372 | ||
| Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study | Q59468822 | ||
| Epidemiology and etiology of bladder cancer | Q73591458 | ||
| Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin | Q83583616 | ||
| P2507 | corrigendum / erratum | Correction for Volkmer et al., Three differentiation states risk-stratify bladder cancer into distinct subtypes | Q93549363 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 2078-2083 | |
| P577 | publication date | 2012-01-19 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Three differentiation states risk-stratify bladder cancer into distinct subtypes | |
| P478 | volume | 109 |
| Q90345895 | A Consensus Molecular Classification of Muscle-invasive Bladder Cancer |
| Q35072270 | A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors |
| Q34708383 | ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| Q103836778 | Advances in bladder cancer biology and therapy |
| Q42484380 | Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis. |
| Q36878683 | Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells |
| Q90441536 | Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients |
| Q37360092 | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
| Q34448168 | Biomarkers for bladder cancer management: present and future. |
| Q37053995 | Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting |
| Q26771263 | Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives |
| Q52810295 | Bladder cancer. |
| Q42465565 | Bladder cancers arise from distinct urothelial sub-populations. |
| Q35735937 | Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance |
| Q49787389 | Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer |
| Q35485418 | CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer |
| Q57452829 | CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer |
| Q94547018 | CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma |
| Q38713728 | Cancer stem cells in prostate cancer |
| Q38943219 | Cellular Hierarchy as a Determinant of Tumor Sensitivity to Chemotherapy |
| Q97074381 | Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit |
| Q41160701 | Claudin-low bladder tumors are immune infiltrated and actively immune suppressed |
| Q89997628 | Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification |
| Q47777684 | Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype |
| Q37215956 | Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium |
| Q47551371 | Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis |
| Q92812554 | Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer |
| Q95321930 | Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers |
| Q93039546 | Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes |
| Q36882005 | FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma |
| Q36546605 | Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. |
| Q40835446 | Genome-Wide Scan for Methylation Profiles in Keloids |
| Q92783364 | Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome |
| Q93068067 | Identification of gene expression logical invariants in Arabidopsis |
| Q49473929 | Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. |
| Q33817493 | Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis |
| Q39028041 | In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival |
| Q92135391 | Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway |
| Q41339763 | Insights from animal models of bladder cancer: recent advances, challenges, and opportunities |
| Q104495363 | Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy |
| Q28088334 | Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise |
| Q37024540 | KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis |
| Q92826166 | Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells |
| Q34433060 | LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types |
| Q35568071 | Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer |
| Q92659257 | Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells |
| Q37317523 | Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis |
| Q35285703 | Modelling bladder cancer in mice: opportunities and challenges |
| Q57175925 | Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy |
| Q38297729 | Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity |
| Q26744343 | Molecular substratification of bladder cancer: moving towards individualized patient management |
| Q35640830 | Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems |
| Q36217643 | Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin |
| Q37358942 | Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. |
| Q26825948 | Normal and neoplastic urothelial stem cells: getting to the root of the problem |
| Q34670535 | Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum |
| Q35612218 | Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas |
| Q39459198 | Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer |
| Q38816754 | Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines |
| Q37696186 | Positive association of collagen type I with non-muscle invasive bladder cancer progression |
| Q38424919 | Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. |
| Q90617471 | Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells |
| Q47406496 | Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy |
| Q92046407 | Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy |
| Q47727562 | Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas |
| Q35730347 | Quantitative Analysis of Differential Proteome Expression in Bladder Cancer vs. Normal Bladder Cells Using SILAC Method |
| Q38693644 | Role of Sonic Hedgehog (Shh) Signaling in Bladder Cancer Stemness and Tumorigenesis |
| Q28080330 | Role of angiogenesis in urothelial bladder carcinoma |
| Q90469821 | SIU-ICUD consultation on bladder cancer: basic science |
| Q41233576 | Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient |
| Q42515074 | Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases |
| Q34505763 | Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling |
| Q42503789 | Stage- and subunit-specific functions of polycomb repressive complex 2 in bladder urothelial formation and regeneration |
| Q42275760 | Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer |
| Q57171093 | Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4 |
| Q50000734 | Subtyping Bladder Cancers: Biology vs Bioinformatics |
| Q38902594 | Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer. |
| Q95785557 | The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer |
| Q91653506 | The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer |
| Q35683471 | The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells |
| Q36579525 | The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. |
| Q36193716 | The power of boolean implication networks |
| Q38202644 | The relationship of cancer stem cells in urological cancers |
| Q99233211 | The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis |
| Q64062159 | Therapeutic Targeting of Collective Invasion in Ovarian Cancer |
| Q64274457 | Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma |
| Q95661266 | Transcriptional profiling of lung macrophages identifies a predictive signature for inflammatory lung disease in preterm infants |
| Q55126311 | Understanding the biology of urothelial cancer metastasis. |
| Q36150692 | Update on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer |
| Q89639841 | UroSEEK gene panel for bladder cancer surveillance |
| Q42514824 | Urothelial Carcinoma Stem Cells: Current Concepts, Controversies, and Methods. |
| Q39097235 | Urothelial generation and regeneration in development, injury, and cancer. |
| Q90339620 | Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity |
| Q97518464 | lncRNA SNHG1 Promotes Basal Bladder Cancer Invasion via Interaction with PP2A Catalytic Subunit and Induction of Autophagy |
| Q91761018 | β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer |
Search more.